Lawrence Wilson

Title: Innovations of Lawrence Wilson in Neuropharmacology

Introduction

Lawrence Wilson is a notable inventor based in Atlanta, GA (US). He has made significant contributions to the field of neuropharmacology, particularly through his innovative research and patenting of compounds that target specific receptors in the brain. His work has implications for various neurological conditions and disorders.

Latest Patents

Lawrence Wilson holds a patent for "GluN2B-subunit selective antagonists of the N-methyl-D-aspartate receptors with enhanced potency at acidic pH." This patent discloses compounds that selectively inhibit GluN2B-containing N-methyl-D-aspartic acid receptors (NM/DARs). The compounds are designed to target GluN2B over other subunits such as GluN2A, GluN2C, and GluN2D. Notably, these compounds exhibit enhanced potency at a more acidic pH compared to physiological pH. The patent also includes pharmaceutical formulations containing these compounds and methods for treating various conditions, including stroke, cerebral ischemia, and neurodegenerative diseases.

Career Highlights

Throughout his career, Lawrence Wilson has worked with esteemed institutions such as Emory University and Neurop, Inc. His research has focused on developing innovative solutions for complex neurological issues, contributing to advancements in medical science.

Collaborations

Lawrence has collaborated with notable professionals in his field, including Dennis C. Liotta and Stephen F. Traynelis. These collaborations have further enriched his research and development efforts.

Conclusion

Lawrence Wilson's contributions to neuropharmacology through his patent and collaborations highlight his commitment to advancing medical science. His work continues to pave the way for innovative treatments for neurological disorders.